Document Detail


Lung cancer genotype-based therapy and predictive biomarkers: present and future.
MedLine Citation:
PMID:  23194040     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.
Authors:
Philip T Cagle; Timothy Craig Allen
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1482-91     Citation Subset:  AIM; IM    
Affiliation:
From the Department of Pathology & Genomic Medicine, The Methodist Hospital, Houston, Texas (Dr Cagle); and the Department of Pathology, University of Texas Health Science Center at Tyler (Dr Allen).
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Worldwide overview of the current status of lung cancer diagnosis and treatment.
Next Document:  In vivo optical coherence tomography: the role of the pathologist.